Skip to main content

Table 2 Patient and treatment characteristics of the case group and control group

From: Dosimetric predictors of temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma: a competing risk study

Variable Case group Control group P value
Median age (y) 49 48 ND
Age range (y) 27–72 28–70 ND
Male 56 (88.9) 56 (88.9) ND
Female 7 (11.1) 7 (11.1) ND
N-classification 0.069
 N0–1 31 (49.2) 41 (65.1)
 N2–3 32 (50.8) 22 (34.9)
AJCC 2010 stage 0.752
 IVA 58 (92.1) 57 (90.5)
 IVB 5 (7.9) 6 (9.5)
Chemotherapy
 Induction 60 (95.2) 56 (88.9) 0.187
 Concurrent 36 (57.1) 42 (66.7) 0.271
 Adjuvant 20 (31.7) 19 (30.2) 1.000
Concurrent cetuximab or nimotuzumab 7 (11.1) 3 (4.8) 0.187
Nasopharynx boost 4 (6.3) 1 (1.6) 0.365a
Overall treatment time (OTT) 0.859
 ≤ 45 25 (39.7) 19 (30.1)
 > 45 38 (60.3) 44 (69.8)
Temporal lobe Dmax (Gy) 75.22 (63.83–80.16) 72.64 (61.35–79.35) < 0.001
Temporal lobe D1cc (Gy) 72.52 (54.47–77.21) 66.81 (54.40–74.95) < 0.001
Temporal lobe V20 (cc) 48.18 (21.26–75.20) 38.06 (15.01–79.18) < 0.001
Temporal lobe V30 (cc) 31.64 (10.22–56.35) 23.94 (8.55–55.09) < 0.001
Temporal lobe V40 (cc) 20.11 (6.09–43.16) 15.09 (5.63–37.47) < 0.001
Temporal lobe V50 (cc) 13.23 (2.76–31.28) 8.84 (2.23–29.56) < 0.001
Temporal lobe V60 (cc) 7.59 (0.2–19.71) 3.65 (0.24–19.45) < 0.001
Temporal lobe V70 (cc) 2, 26 (0–9.18) 0.26 (0–8.22) < 0.001
  1. Abbreviation: AJCC American Joint Committee on Cancer, ND not done;
  2. aP value with Fisher Exact Test
  3. Values are number (percentage) or median (range)